Exubrion Taps Veteran Leader to Scale Revolutionary Arthritis Therapy for Dogs

ATLANTA, GA – July 22, 2026 – In a move signaling a strategic push for aggressive market expansion, Exubrion Therapeutics has appointed Gregory Taglialatela as its new Chief Commercial Officer. The promotion places an industry veteran at the helm of commercial strategy for Synovetin OA®, a novel therapy poised to disrupt the multi-billion-dollar canine osteoarthritis market. This leadership change comes at a pivotal moment, as the intersection of advanced medical technology and the deepening human-animal bond creates unprecedented demand for more effective, long-lasting solutions for aging pets.

The Shifting Landscape of Pet Pain Management

Osteoarthritis (OA) is a debilitating reality for a significant portion of the aging canine population, causing chronic pain and reduced mobility. The market dedicated to alleviating this suffering is not just large; it's rapidly expanding. Valued at an estimated $4.17 billion in 2026, the canine arthritis treatment sector is projected to grow to over $7 billion by 2034. This growth is fueled by two powerful trends: the “humanization” of pets, where owners view their animals as family members deserving of advanced medical care, and a corresponding increase in pet healthcare expenditure.

For decades, the standard of care has been dominated by non-steroidal anti-inflammatory drugs (NSAIDs) like Boehringer Ingelheim’s Metacam® and Zoetis’s once-dominant Rimadyl®. While effective for many, these daily oral medications can pose challenges related to owner compliance and potential long-term side effects.

The competitive landscape was recently upended by the arrival of monoclonal antibodies (mAbs) targeting Nerve Growth Factor (NGF), a key driver of pain. Zoetis, a giant in the animal health space, has made significant inroads with Librela®, a monthly injectable that has treated over a million dogs in the U.S. since its 2023 launch, and Lenivia®, a newer therapy offering up to three months of relief. These products have reshaped veterinary approaches to pain management, offering an alternative to daily pills. It is within this dynamic and highly competitive environment that Exubrion Therapeutics is positioning Synovetin OA as a paradigm-shifting alternative.

A New Frontier in Arthritis Care: The Science of Synovetin OA

Unlike therapies that require daily, monthly, or quarterly administration, Synovetin OA introduces a fundamentally different approach. It is a one-time, injectable treatment that can provide pain relief for up to a full year. The therapy is a form of radiosynoviorthesis, a procedure long used in human medicine, adapted for veterinary use. It involves the intra-articular injection of microscopic particles of tin-117m, a medical radioisotope.

Once inside the joint, these particles are absorbed by synovioctyes—specialized cells in the joint lining that are a primary source of inflammation in arthritic joints. The localized, low-level radiation emitted by the tin-117m deactivates these pro-inflammatory cells, breaking the cycle of pain and inflammation at its source. This targeted mechanism not only provides profound and long-lasting pain relief but, according to the company, also helps slow the progression of the disease itself.

This innovative approach offers a compelling value proposition for both veterinarians and pet owners. It eliminates the need for daily medication and frequent veterinary visits for injections, improving convenience and compliance. However, the technology's advanced nature also presents a unique logistical hurdle: because it involves a radioactive material, Synovetin OA can only be administered at specially certified veterinary treatment centers. This makes the strategy for expanding access a critical component of its commercial success.

A Strategic Appointment for a Critical Growth Phase

The promotion of Gregory Taglialatela is a clear indicator of Exubrion's intent to navigate these challenges and accelerate growth. With over 15 years in the animal health industry and a series of escalating leadership roles since joining the company in 2022—including Sales Manager and National Account Director—Taglialatela possesses a deep, internal understanding of the product and its market potential.

“Gregory has consistently demonstrated exceptional leadership, strategic vision, and an unwavering commitment to improving the lives of pets suffering from osteoarthritis,” said Laurie McRay, executive chair of Exubrion Therapeutics. “His deep understanding of our business, strong industry relationships, and proven ability to execute make him the ideal leader to drive our next phase of growth.”

In his new role, Taglialatela is tasked with leading national sales, managing key accounts, and spearheading strategic initiatives to broaden the therapy's availability. His focus will be on expanding the network of veterinary treatment centers qualified to administer Synovetin OA and strengthening industry partnerships.

“I am honored to take on this role at such an important point in Exubrion’s growth,” said Taglialatela. “I have seen firsthand the difference Synovetin OA can make for dogs living with osteoarthritis and for the veterinary teams caring for them. I look forward to working with our customers, treatment-center partners and leadership team to expand access to this innovative therapy and help more dogs return to comfortable, active lives.”

Navigating the Path to Broader Adoption

Under Taglialatela's commercial leadership, Exubrion's primary challenge will be to carve out a significant market share against well-entrenched and heavily marketed competitors. Success will hinge on a multi-faceted strategy that effectively communicates the unique, long-term benefits of Synovetin OA to a veterinary community that now has several advanced options at its disposal. Educating practitioners and pet owners on the science behind the therapy and its potential role within a multimodal pain management plan will be paramount.

Furthermore, scaling the network of certified treatment centers is the central logistical challenge that will dictate the therapy's accessibility. Taglialatela's experience in business development will be crucial in building the infrastructure necessary to make Synovetin OA a viable option for a broader base of patients currently limited by geography.

As the line between pet and family member continues to blur, the demand for innovations that offer not just treatment, but a restored quality of life, will only intensify. Exubrion's focused bet on a long-acting, disease-modifying therapy, now guided by a new commercial chief, represents a significant development in the ongoing effort to help aging companions live more comfortable and active lives.